Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 12 EP applications Dawn Caroline Goff has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after November 16, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12838132

ANTIBACTERIAL COMPOUNDS

IPC classification:
A01N 57/00
Applicant:
Shionogi & Co. Limited (Shionogi Seiyaku Kabushiki-gaisha)
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
PATENT GRANTED
EP12859359

METHOD OF TREATING CANCER WITH MAGEA3 IMMUNOTHERAPEUTIC WITH BRAF INHIBITOR AND/OR MEK INHIBITOR

IPC classification:
A61K 39/00, A61K 31/54, A01N 43/40
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13743888

ANTACID TABLET

IPC classification:
A61K 33/10
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13718590

NOVEL COMPOUNDS

IPC classification:
A61K 31/18, C07D 319/12, C07D 309/10, C07D 309/06, C07D 309/04, C07D 265/32, C07D 265/30, C07D 239/54, C07D 207/08, C07D 205/04, C07C 311/44, C07C 311/29, C07C 311/21, A61P 17/06, A61P 11/06
Applicant:
Glaxo Group Limited
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13835019

METHOD OF ADJUVANT CANCER TREATMENT

IPC classification:
A61K 31/519, A61K 31/506, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13820853

2 SUBSTITUTED CEPHEM COMPOUNDS

IPC classification:
A61K 31/546, C07D 505/24, C07D 501/50
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14846138

COMBINATION DRUG THERAPY

IPC classification:
C07D 413/10, C07D 233/86, A61K 31/535, A61K 31/4166
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14809779

NOVEL MILK BEVERAGE COMPOSITION COMPRISING CREATINE

IPC classification:
A23C 11/10, A23C 9/154, A23C 9/152
Applicant:
Glaxo Group Limited
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16860592

NOVEL OCCLUSIVE FORMULATIONS

IPC classification:
A61Q 19/00, A61K 31/215, A61K 8/37
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
Request for examination was made
EP16860596

NOVEL METHOD OF USE AND COMPOSITIONS

IPC classification:
A61Q 19/00, A61K 31/215, A61K 8/37
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
Request for examination was made
EP16860588

NOVEL OCCLUSIVE COMPOSITIONS

IPC classification:
A61Q 19/00, A61K 31/215, A61K 8/37
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
Request for examination was made
EP16864840

NOVEL FORMULATIONS

IPC classification:
C07C 69/54, A61K 31/717, A61K 31/327
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature